Naoxintong restores collateral blood flow in a murine model of hindlimb ischemia through PPARδ-dependent mechanism

Chen, Lu; Zhang, Lusha; Fang, Zhirui; Li, Chunxiao; Yang, Yue; You, Xingyu; Song, Min; Coffie, Joel Wake; Zhang, Liyuan; Gao, Xiumei; Wang, Hong

doi:10.1016/j.jep.2018.08.032

Cited by 9 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a significant increase in ovarian blood flow in the rosiglitazone group. Based on our results and those of other studies [13,36], it may be speculated that rosiglitazone increases ovarian blood flow after hysterectomy. Additionally, the amount of follicular increase in the hysterectomy group was not seen in the rosiglitazone group.…”

Section: Discussionsupporting

confidence: 84%

“…PPAR-γ receptor is a ligand-dependent transcription factor and a member of the nuclear receptor superfamily. Acting as sensors of hormones, vitamins, endogenous metabolites, and xenobiotic compounds, the nuclear receptors control the expression of a very large number of genes [10][11][12][13]36]. Although the literature contains many publications that indicate the antioxidant and antiinflammatory effects of PPAR-γ agonists on other organs [8,9], there is no study about its potential effects on posthysterectomy ovaries.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study

Gündoğdu¹,

Tapisiz²,

Dilbaz³

et al. 2020

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: To evaluate the effects of hysterectomy on rat ovaries and the possible protective role of peroxisome proliferatoractivated receptor gamma (PPAR-γ) agonist-rosiglitazone against ovarian reserve decrement. Materials and methods: Forty-five adult Wistar albino rats were randomly divided into three groups. Hysterectomy was performed (n = 15) in group 1 [H]; 1 mg/kg/day PPAR-γ agonist/rosiglitazone was used for 50 days after hysterectomy (n = 15) in group 2 [H + R]; a sham operation was performed (n = 15) in group 3 [control, C]. Blood samples were collected for anti-Müllerian hormone (AMH) evaluation in all groups and simultaneous ovarian Doppler examination was performed in [H] and [H + R] groups before and after (50 days) hysterectomy. All animals were sacrificed to obtain ovaries for histological examination. Results: AMH levels were found to be significantly decreased at postoperative day 50 in all groups (P < 0.05). Histopathologic analysis showed that primary, preantral, and antral follicle counts were significantly higher in the [H] group as compared to the [C] and [H + R] groups (P < 0.05). There was no significant difference between the [C] and [H + R] groups in terms of follicle numbers (P > 0.05). In the ovarian Doppler blood flow analysis, all parameters were significantly decreased in group [H] (P < 0.05), but not in the [H + R] group (P > 0.05) on postoperative day 50. Conclusion: Hysterectomy affects the histopathological structure of rat ovaries and PPAR-γ agonist-rosiglitazone improves the ovarian Doppler blood flow parameters.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study

Gündoğdu¹,

Tapisiz²,

Dilbaz³

et al. 2020

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Five years later, Han and colleagues claimed that the role of PPARβ/δ activation in vascular biology and skeletal muscle is widely unknown and reported increased angiogenesis and muscle regeneration in a hindlimb ischemia model in mice in response to GW501516 treatment, which was attributed to direct MMP9 activation followed by degradation of insulin-like growth factor-binding protein 3 and resulting IGF-1 receptor activation in surrounding target cells [ 100 ]. Also treatment with the PPARβ/δ agonist GW0742 or the pan PPAR agonist bezafibrate or a Chinese traditional medicine compound which activates PPARβ/δ increased capillary density in the hindlimb ischemia model in control and diabetic rats and mice [ 101 , 102 , 103 ]. In the heart, pharmacological PPARβ/δ activation induced rapid onset angiogenesis and cardiac hypertrophy without functional impairment, which we could attribute to direct transcriptional activation of calcineurin [ 104 ].…”

Section: Ppars and Cardiovascular Diseasementioning

confidence: 99%

PPARs and Angiogenesis—Implications in Pathology

Wagner

2020

IJMS

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptors (PPARs) belong to the family of ligand-activated nuclear receptors. The PPAR family consists of three subtypes encoded by three separate genes: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs are critical regulators of metabolism and exhibit tissue and cell type-specific expression patterns and functions. Specific PPAR ligands have been proposed as potential therapies for a variety of diseases such as metabolic syndrome, cancer, neurogenerative disorders, diabetes, cardiovascular diseases, endometriosis, and retinopathies. In this review, we focus on the knowledge of PPAR function in angiogenesis, a complex process that plays important roles in numerous pathological conditions for which therapeutic use of PPAR modulation has been suggested.

show abstract

“…However, these treatments cannot meet the needs with all patients. To improve the quality of life and prognosis of patients with PAD, it is necessary to carry out effective drug treatment [6].…”

Section: Introductionmentioning

confidence: 99%

Protection against peripheral artery disease injury by Ruan Jian Qing Mai formula via metabolic programming

Chen

Liang

et al. 2020

Biotech and App Biochem

View full text Add to dashboard Cite

Ruan Jian Qing Mai formula (RJQM), a multicomponent herbal formula, has been widely used to treat peripheral arterial disease (PAD) in China. However, its active compounds and mechanisms of action are still unknown. First, RNA sequencing analysis of 15 healthy and 16 PAD samples showed that 524 PAD differential genes were significantly enriched in Go Ontology (ribonucleotide metabolic process, oxidoreductase complex, and electron transfer activity), Kyoto Encyclopedia of Genes and Genomes (KEGG) and GSEA pathways (OXPHOS and TCA cycle), miRNA (MIR183), and kinase (PAK6). Fifty‐three active ingredients in RJQM had similar structures to the seven drug molecules in CLUE. Then, network topology analysis of the 53 components‐target‐pathway‐disease network yielded 10 active ingredients. Finally, computational toxicity estimations showed that the median lethal dose (LD50) of the 10 active ingredients was above 1000 mg/kg, and eight of them did not cause hepatotoxicity, mutagenicity, carcinogenicity, cytotoxicity, and immunotoxicity nor activate 12 toxic pathways. In conclusion, RJQM has a protection effect on PAD by regulating a complex molecular network. Part of the mechanism is associated with the regulation of OXPHOS by 10 active components, which may alleviate mitochondrial dysfunction and pathological metabolic programming.

show abstract

Naoxintong restores collateral blood flow in a murine model of hindlimb ischemia through PPARδ-dependent mechanism

Cited by 9 publications

References 43 publications

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study

PPARs and Angiogenesis—Implications in Pathology

Protection against peripheral artery disease injury by Ruan Jian Qing Mai formula via metabolic programming

Contact Info

Product

Resources

About